Guj. Terce Labs.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE499G01013
NSEID:
BSEID: 524314
View on BSE

INR

34.88

0.38 (1.1%)

BSENSE

Jun 03, 03:30 PM

BSE+NSE Vol: 8.49 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ANG Lifesciences

Guj. Terce Labs.

Ishita Drugs

Centuple Global

Medi Caps

Shree Ganesh Bio

Venmax Drugs

Welcure Drugs

Lasa Supergeneri

Chandra Bhagat

Medicamen Organ.

Why is Gujarat Terce Laboratories Ltd ?

Weak Long Term Fundamental Strength with a 13.52% CAGR growth in Net Sales over the last 5 years

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.21

Underperformed the market in the last 1 year

Even though the market (BSE500) generated negative returns of -1.52% in the last 1 year, its fall in the stock was much higher with a return of -31.61%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Guj. Terce Labs. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Guj. Terce Labs.

-31.61%

-0.48

65.28%

Sensex

-7.92%

-0.61

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.52%

EBIT Growth (5y)

25.66%

EBIT to Interest (avg)

1.21

Debt to EBITDA (avg)

0.73

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

4.64

Tax Ratio

26.97%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

30.11%

ROE (avg)

7.71%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.80

EV to EBIT

7.32

EV to EBITDA

6.48

EV to Capital Employed

3.57

EV to Sales

0.51

PEG Ratio

0.03

Dividend Yield

ROCE (Latest)

48.83%

ROE (Latest)

25.13%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

PAT(Latest six months)

Higher at Rs 1.09 cr

-1What is not working for the Company

NET SALES(Q)

At Rs 11.40 cr has Fallen at -5.8% (vs previous 4Q average

Loading Valuation Snapshot...

Here's what is working for Guj. Terce Labs.

Profit After Tax (PAT) - Latest six months

At Rs 1.09 cr has Grown at 145.59%

Year on Year (YoY)

MOJO Watch

PAT trend is very positive

PAT (Rs Cr)

Profit After Tax (PAT) - Latest six months

Higher at Rs 1.09 cr

than preceding 12 month period ended Mar 2026 of Rs -1.02 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Guj. Terce Labs.

Net Sales - Quarterly

At Rs 11.40 cr has Fallen at -5.8% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 12.10 Cr

MOJO Watch

Near term sales trend is negative

Net Sales (Rs Cr)